510(k) device
Access AMH
Beckman Coulter, Inc. · Anti-Müllerian Hormone Test System (PQO, Class II) · First FDA decision Nov 13, 2017, newest Feb 3, 2023Infertility
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
2
510(k) pathway
Device trials
0
Naming "Access AMH"
MAUDE reports
0
Brand "Access AMH", since 2015
PubMed studies
22
Mentioning "Access AMH"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Access AMH
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 2 of 2 decisions filed under this name.
- Access AMH510(k)
K223679 · Decided Feb 3, 2023 · 57 days after receipt
Device type: Anti-Müllerian Hormone Test System (PQO) · Laboratory Medicine & Pathology
- Access AMH510(k)
K170524 · Decided Nov 13, 2017 · 264 days after receipt
Device type: Anti-Müllerian Hormone Test System (PQO) · Laboratory Medicine & Pathology
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "Access AMH", any status and sponsor, newest update first.
No registered device study names "Access AMH".
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Access AMH", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code PQO
14 reports: 14 malfunction, 0 injury, 0 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Access AMH"[tiab]. The summary above synthesizes these.
- Age-related diagnostic threshold of anti-Müllerian hormone for polycystic ovarian syndrome.
Kakkad V, Reddy NS, Nihlani H, et al. · Int J Gynaecol Obstet · 2021Observational Study
- The Stability of the Anti-Müllerian Hormone in Serum and Plasma Samples under Various Preanalytical Conditions.
Vrzáková R, imánek V, Topolčan O, et al. · Diagnostics (Basel) · 2023
- Two new automated, compared with two enzyme-linked immunosorbent, antimüllerian hormone assays.
Nelson SM, Pastuszek E, Kloss G, et al. · Fertil Steril · 2015Evaluation Study, Research Support, Non-U.S. Gov't
- Development of a digital anti-Müllerian hormone immunoassay: ultrasensitive, accurate and practical strategy for reduced ovarian reserve monitoring and assessment.
Kuang X, Wei L, Huang Y, et al. · Talanta · 2023
- Differing performance of two assays for the measurement of anti-Mullerian hormone in premenopausal women: A cross-sectional study.
Bell RJ, Skiba MA, Sikaris K, et al. · Clin Endocrinol (Oxf) · 2021Research Support, Non-U.S. Gov't
- The interchangeability of two assays for the measurement of anti-Müllerian hormone when personalizing the dose of FSH in in-vitro fertilization cycles.
La Marca A, Tolani AD, Capuzzo M · Gynecol Endocrinol · 2021
- Performance of anti-Müllerian hormone (AMH) levels measured by Beckman Coulter Access AMH assay to predict oocyte yield following controlled ovarian stimulation for in vitro fertilization.
Asada Y, Tsuiki M, Sonohara M, et al. · Reprod Med Biol · 2019
- Measurement of serum anti-Müllerian hormone by revised Gen II or automated assay: Reproducibility under various blood/serum storage conditions.
Lee JY, Kim CH, Choe SA, et al. · Clin Exp Reprod Med · 2023
- A prospective study of anti-mullerian hormone and other ovarian and adrenal hormones in adult female acne.
Bansal P, Sardana K, Arora P, et al. · Dermatol Ther · 2020
- Age-specific reference ranges of serum anti-müllerian hormone in healthy women and its application in diagnosis of polycystic ovary syndrome: a population study.
Li H, He YL, Li R, et al. · BJOG · 2020Observational Study, Research Support, Non-U.S. Gov't
- Multi-center clinical evaluation of the Access AMH assay to determine AMH levels in reproductive age women during normal menstrual cycles.
Gracia CR, Shin SS, Prewitt M, et al. · J Assist Reprod Genet · 2018Multicenter Study
- Performance characteristics of the Access AMH assay for the quantitative determination of anti-Müllerian hormone (AMH) levels on the Access* family of automated immunoassay systems.
Demirdjian G, Bord S, Lejeune C, et al. · Clin Biochem · 2016
Other devices of this type
Also filed under product code PQO.
- ADVIA Centaur® Anti-Müllerian Hormone (AMH)Siemens Healthcare Diagnostics, Inc. · 510(k) 2023
- Elecsys AMHRoche Diagnostics · 510(k) 2022
- Elecsys AMH, AMH CalSet, PreciControl AMH, AMH CalCheck 5Roche Diagnostics · De Novo 2016
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.